367
Views
23
CrossRef citations to date
0
Altmetric
Review

Olmesartan/amlodipine: a review of its use in the management of hypertension

Pages 183-192 | Published online: 29 Mar 2011

Figures & data

Figure 1 Mean change in seated systolic blood pressure (SeSBP) from baseline to weeks 2, 4, 6 and 8 with olmesartan (OLM) and amlodipine (AML) monotherapy and olmesartan/amlodipine combination therapy.

Notes: Based upon data presented by Chrysant et al.Citation46,Citation47 For clarity, some dosages and combinations have been omitted from this Figure.
Figure 1 Mean change in seated systolic blood pressure (SeSBP) from baseline to weeks 2, 4, 6 and 8 with olmesartan (OLM) and amlodipine (AML) monotherapy and olmesartan/amlodipine combination therapy.

Table 1 The COACH trial – change in seated diastolic blood pressure (SeDBP) and seated systolic blood pressure (SeSBP) from baseline to week 8 in the intent-to-treat population (last observation carried forward)Citation46

Table 2 The COACH trial – patients achieving the blood pressure target (<140/90 mmHg for patients with uncomplicated hypertension; <130/80 mmHg for patients with diabetes) after eight weeks of treatment (last observation carried forward)Citation46

Figure 2 Olmesartan/amlodipine combination therapy versus amlodipine monotherapy – mean change from baseline in seated blood pressure after eight weeks of randomized, double-blind treatment.Citation49

Notes: *p < 0.05; **p < 0.0001 vs AML 5 mg monotherapy.
Abbreviations: AML, amlodipine; OLM, olmesartan; SeBP, seated blood pressure; SeDBP, seated diastolic blood pressure; SeSBP, seated systolic blood pressure.
Figure 2 Olmesartan/amlodipine combination therapy versus amlodipine monotherapy – mean change from baseline in seated blood pressure after eight weeks of randomized, double-blind treatment.Citation49

Figure 3 Olmesartan/amlodipine combination therapy versus amlodipine monotherapy – mean change from baseline in seated systolic blood pressure after eight weeks of randomized, double-blind, uptitrated treatment.Citation49

Notes: Uptitration of non-responders: patients whose BP was not adequately controlled (SeDBP ≥90 mmHg and SeSBP ≥140 mmHg) during randomized treatment in Period II.
Abbreviations: AML, amlodipine; OLM, olmesartan; SeSBP, seated systolic blood pressure.
Figure 3 Olmesartan/amlodipine combination therapy versus amlodipine monotherapy – mean change from baseline in seated systolic blood pressure after eight weeks of randomized, double-blind, uptitrated treatment.Citation49

Figure 4 Mean levels of seated systolic blood pressure (SeSBP) at the start (week 0) and end of treatment (week 52) according to baseline SeSBP in all patients treated with olmesartan/amlodipine combination therapy in a randomized, double-blind study.Citation58

Note: Adapted with permission from Mourad and Le Joune. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy. Clin Drug Investig. 2009;29(6):419–425.
Figure 4 Mean levels of seated systolic blood pressure (SeSBP) at the start (week 0) and end of treatment (week 52) according to baseline SeSBP in all patients treated with olmesartan/amlodipine combination therapy in a randomized, double-blind study.Citation58

Figure 5 Proportion of patients who achieved the cumulative seated blood pressure (SeBP) goal of 140/90 mmHg in the BP-CRUSH study.Citation59

Abbreviations: AML, amlodipine; HCTZ, hydrochlorothiazide; OLM, olmesartan.
Figure 5 Proportion of patients who achieved the cumulative seated blood pressure (SeBP) goal of 140/90 mmHg in the BP-CRUSH study.Citation59